Summary & Overview
HCPCS Level II J9030: BCG Intravesical Instillation, 1 mg
HCPCS Level II code J9030 denotes the intravesical administration of BCG (bacillus Calmette-Guérin), 1 mg, and is central to bladder cancer intravesical therapy practices nationwide. The code captures drug administration events where BCG is instilled directly into the bladder, typically in outpatient hospital clinics or ambulatory clinic settings. Nationally, accurate reporting of this HCPCS Level II code supports clinical tracking, quality measurement, and payer processing for a commonly used intravesical antineoplastic therapy.
This analysis covers coverage and billing considerations across major payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will find a concise overview of clinical context for use of J9030, common service settings, related procedural and evaluation codes, and operational notes relevant to billing workflows. The publication addresses coding relationships and common modifiers used with drug administration claims, outlines pertinent diagnosis links for intravesical BCG therapy, and provides comparisons to related administration and instillation procedure codes.
Where specific commercial or program-level policy details are unavailable, the publication notes limitations as "Data not available in the input." The content is intended to clarify how J9030 is applied in clinical billing and coding processes and to inform billing, coding, and revenue cycle stakeholders of the code's role in documenting intravesical BCG therapy.
Billing Code Overview
HCPCS Level II code J9030 represents BCG live intravesical instillation, 1 mg, a drug administration service used for intravesical therapy. This code is used to report the instillation of bacillus Calmette-Guérin (BCG) directly into the bladder as a therapeutic agent.
Service type: Drug administration (intravesical therapy)
Typical site of service: Hospital outpatient or clinic settings (Place of Service 19 or 11).
Clinical & Coding Specifications
Clinical Context
A patient with known non–muscle-invasive bladder cancer scheduled for intravesical therapy with Bacillus Calmette-Guérin (BCG). The patient arrives to a hospital outpatient department (POS 19) or clinic (POS 11) for same‑day intravesical instillation. After verification of identity, indications and consent, a bladder catheter may be placed, the urinary bladder drained, and the prepared dose of BCG (HCPCS Level II code J9030, 1 mg) instilled intravesically. The patient is monitored briefly for immediate adverse reactions, allowed to retain the instillate per protocol, then voids and is discharged with post‑instillation instructions. Documentation includes diagnosis linkage (for example D09.0 or C67.9), drug administration details (lot number, dose, lot/discard if applicable), route (intravesical), and any modifier usage (for instance JW when part of the drug is discarded).
Coding Specifications
-
HCPCS Level II code: Always reported as HCPCS Level II code
J9030for BCG live intravesical instillation, 1 mg. -
Common modifiers and use cases:
-
JW— Drug amount discarded/not administered to any patient. Use when a portion of the single‑use vial or dose is prepared but partially discarded; document the discarded amount and reason. -
59— Distinct Procedural Service. Use when a separately identifiable service or procedure is performed on the same day that is not usually bundled with the intravesical drug administration; document why the service is distinct. -
Associated provider taxonomies and specialties:
| Taxonomy Code | Specialty |
|---|---|
207RH0003X | Hematology & Oncology Physician |
208600000X | Urology Physician |
207RX0202X | Medical Oncology Physician |
Related Codes
-
51720— Bladder instillation of anticarcinogenic agentThis procedure code describes the physical instillation of an anticarcinogenic agent into the bladder and is the direct procedural counterpart to reporting the service; it may be reported when documenting the instillation procedure in addition to the drug code where payer rules allow.
-
96401— Chemotherapy administration, subcutaneous or intramuscularThis chemotherapy administration code is for different routes (subcutaneous or intramuscular) and is not directly used for intravesical therapy but appears as a related administration family code.
-
96402— Chemotherapy administration, intravenous pushThis code describes intravenous push administration and is listed as a related administration code for chemotherapy services; it is an alternative route code when applicable but not for intravesical instillation.
-
99213— Established patient office or other outpatient visit, level 3This evaluation and management code may be used for the outpatient visit component when a clinician provides a qualifying evaluation on the same day as the intravesical drug administration; documentation must support the level of E/M service.
Note: The primary drug charge is reported with HCPCS Level II code J9030, with procedural and visit codes used according to clinical workflow and payer billing rules.
Related Diagnoses
-
C67.9— Malignant neoplasm of bladder, unspecifiedRelevant because intravesical BCG is used to treat superficial bladder cancer and is commonly linked to a bladder malignancy diagnosis.
-
D09.0— Carcinoma in situ of bladderRelevant because carcinoma in situ of the bladder is an indication for intravesical BCG therapy to reduce recurrence and progression.
-
Z51.11— Encounter for antineoplastic chemotherapyRelevant because the intravesical instillation is a form of antineoplastic therapy and encounters for such therapy are coded with this diagnosis when appropriate.
-
Z85.51— Personal history of malignant neoplasm of bladderRelevant when the patient has a prior bladder cancer history and may be receiving surveillance or intravesical therapy for recurrence prevention or residual disease management.
National Reimbursement Benchmarks
National mean rates for HCPCS Level II code J9030 show that Medicare’s mean of $3.00 is lower than BUCA (average commercial) at $5.50, with Aetna notably higher at $11.66. The full payer-by-payer breakdown is provided in the table and chart below.
Rate dispersion (P75 minus P25) is tightest for Medicare and Cigna Health (both zero spread between the 25th and 75th percentiles) and widest for Blue Cross Blue Shield and UnitedHealthcare (spreads of $0.80 and $1.00 respectively). Aetna’s percentiles indicate a skew in mean versus central tendency, as its mean is far above its 25th–75th range. The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.